Mangoceuticals gets Nasdaq bid-price extension to Feb 1, 2027; notes Nuclea Energy deal

MANGOCEUTICALS, INC.

Nasdaq granted 180-day extension until Feb 1, 2027 to meet $1 minimum bid price for 10 consecutive days.
Company meets all other Nasdaq listing requirements except the bid price rule.
Company may effect a reverse stock split if needed to cure the deficiency.
Company continues to advance business combination with Nuclea Energy Inc. (Morpheus microreactor).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.